

Capitalised terms used in this announcement have the meanings given to them in the announcement made at 9.00 a.m. EET 3 February 2026 regarding the amortisation payment and approval of share subscriptions based on special rights, unless the context provides otherwise.

Turku, Finland – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company developing novel immunotherapies, has, as announced earlier today on 3 February 2026, approved the exercise of 909,517 Special Rights entitling to 909,517 new Shares, for an aggregate subscription price of EUR 1,549,998.87.

In total 909,517 new shares in the Company have today on 3 February 2026 been registered in the Finnish Trade Register. The shares rank *pari passu* in all respects with the existing shares of the Company. Following the issuance, the aggregate number of ordinary shares in the Company is 119,472,660. Shares held in treasury by the Company do not confer a right to dividends or other shareholder rights. Following the registration, the Company continues to have 3,688,699 shares in treasury and therefore, the total number of voting rights in Faron is 115,783,961 (the “**Number of Shares and Votes**”). This figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify an interest in, or a change to their interest in, the Number of Shares and Votes of the Company.

Trading in the new shares is expected to commence on First North and AIM on or around 5 February 2026.

For more information, please contact:

IR Partners, Finland
(Media)

+358 50 553 9535 / +44 7 469 766 223
kare.laukanen@irpartners.fi

Kare Laukanen

FINN Partners, US
(Media)Â
Alyssa PaldoÂ

+1 847 791-8085Â
alyssa.paldo@finnpartners.com

Cairn Financial Advisers LLP
(Nominated Adviser and Broker)

+44 (0) 207 213 0880

Sandy Jamieson, Jo Turner

Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
Juha Karttunen
Jukka JÃ¤rvelÃ¤

+358 (0)40 555 4727
+358 (0)50 553 8990

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexarabilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexarabilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.